(Reuters) - Hard disk drive maker Western Digital Corp forecast current-quarter revenue largely above analysts' expectations as higher demand for internet storage more than offsets the effects of a fall in personal computer sales.
The company forecast fourth-quarter earnings of $1.65 to $1.80 per share on revenue of $3.55 billion to $3.65 billion.
Analysts on average were expecting earnings of $1.74 per share on revenue of $3.58 billion, according to Thomson Reuters I/B/E/S.
Hard drive sales have been hit as consumers buy fewer personal computers and increasingly shift to smartphones.
Technology tracking firm International Data Corp said earlier this month that PC sales fell 14 percent in the first three months of the year, the biggest decline in two decades of keeping records.
Western Digital, which dominates the hard disk drive market along with Seagate Technology Plc, however, said it expected a 3 percent unit growth rate in hard drives.
"It appears the hard drive business is not suffering as much. That is because of the growth of the cloud and digital data," Noble Financial Capital Markets analyst Mark Miller said.
The demand for storage is growing at the rate of 30 percent annually, Miller added.
The company counts Hewlett-Packard Co as its top customer.
Net income for Western Digital fell to $391 million, or $1.60 per share, in the third quarter, from $483 million, or $1.96 per share, a year earlier.
Revenue rose 24 percent to $3.76 billion.
Excluding items, it earned $2.10 cents per share.
Analysts on average had expected earnings of $1.77 per share on revenue of $3.61 billion.
Hard disk drive shipments rose 36 percent to 60.2 million units.
Western Digital shares were up 3 percent in extended trading after closing at $52.90 on the Nasdaq on Wednesday.
(Reporting by Supantha Mukherjee in Bangalore; Editing by Maju Samuel and Don Sebastian)
NEW YORK (AP) ? Stock futures rose Thursday with U.S. corporate earnings continuing to impress.
Dow Jones industrial futures rose 58 points to 14,673. The broader S&P futures added 7.8 points to 1,581.90. Nasdaq futures are up 18 points to 2,842.
On top of strong earnings from the likes of Harley-Davidson, Southwest Airlines and Dow Chemical, the government said that unemployment benefit applications fall to 339,000, second-lowest level in 5 years.
That was better than most economists had expected and further tamped down apprehensions about a terrible jobs report from March.
There are more earning on the way in one of the busiest weeks of the quarter for U.S companies.
Also reporting Thursday are UPS, United Continental, Starbucks and Expedia.
For those who were worried the day would never come -- the T-Mobile (U.S.) HTC One S is finally getting Android 4.1.1. As confirmed in our HTC One S forums, the sizable (675-megabyte) update brings Jelly Bean, with all its bells and whistles, along with any number of bugfixes. (As of this writing, we're waiting on T-Mobile to post the full changelog.)
The update's a Wifi-only deal, so fire up the router and get downloading.
Apr. 24, 2013 ? Researchers at the University of Cincinnati have found that targeted screening for populations with a higher estimated prevalence for hepatitis C may be cost-effective.
These findings, published in the April 24, 2013, online edition of the journal Clinical Infectious Diseases, indicate that targeted screening for chronic hepatitis C virus infection is cost-effective when the prevalence of hepatitis C in a population exceeds 0.84 percent (84/10,000).
The study further demonstrates how a screening tool, which can be incorporated into an electronic health record, can target such patients and help in preventing the spread of the illness.
Mark Eckman, MD, Alice Margaret Posey Professor of Internal Medicine, professor in the division of general internal medicine and UC Health physician, and Kenneth Sherman, MD, PhD, Robert & Helen Gould Endowed Chair, professor in the division of digestive diseases and UC Health physician, co-authored the study.
"Hepatitis C is the most common chronic blood-borne infection in the United States and will become an increasing source of morbidity and mortality with aging of the infected population," says Sherman, adding that hepatitis C is a viral disease that leads to inflammation of the liver and can be spread through exchange of bodily fluids with an infected person.
"Our objective in this study was to develop decision analytic models, exploring the cost-effectiveness of screening in populations with varying prevalence of hepatitis C and risks for liver fibrosis -- or scarring -- in those with the illness who do not receive treatment. Liver fibrosis results in a damaged liver, and the patient eventually needs a transplant, increasing cost of care."
Researchers developed a computerized Markov state transition model -- a mathematical framework for modeling decision-making in situations where outcomes are partly due to chance and partly under the control of a decision maker -- to examine screening in a U.S. community whose residents showed no symptoms.
"The base case was an ethnically and gender-mixed adult population with no prior knowledge of diagnosis: 49 percent male, 78 percent white, 13 percent black and 9 percent Hispanic, with a mean age of 46 years," says Eckman.
The model explored strategies of screening followed by guideline-based treatment, if needed, and not screening. Effectiveness was measured in quality-adjusted life years (QALYs) -- accounting for both duration of survival and quality of life -- and costs were measured in U.S. dollars.
"In the base case, screening followed by guideline-based treatment -- using boceprevir as the standard antiviral treatment -- of those with chronic hepatitis C infection cost roughly $47,000 per QALY -- a 'cost-effective' result," says Eckman. "The overall hepatitis C prevalence in the U.S. is reported to be between 1.3 and 1.9 percent, but prevalence varies among patients with different risk factors."
He continues that the marginal cost-effectiveness ratio (mCER) of screening decreases as prevalence increases.
"Below a prevalence of 0.84 percent within a population, the mCER is greater than the generally accepted societal willingness-to-pay threshold of $50,000 per QALY," he says. "Therefore, it is not considered highly cost-effective. However, by targeting screening in populations with a higher estimated prevalence, screening and subsequent treatment of those infected would be cost effective."
"Recently released guidelines by the Centers for Disease Control and Prevention advocate 'birth-cohort' focused screening for those born between 1945 and 1965. However, such a strategy may miss screening higher risk patients born in years outside of this cohort," Eckman adds. "Alternatively, patients with no risk factors for hepatitis C infection, other than their membership in the 'birth cohort,' may be at a low enough risk to make their screening less cost-effective."
Eckman and Sherman "argue for the development and proliferation of tools to assist in the implementation of guidelines. The increasing use of electronic health records and computerized order entry create new opportunities to marry guidelines to practice."
"Perhaps in this manner, targeted and cost-effective screening can become a reality," says Eckman.
This work was supported in part by a research grant from the Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp.
Eckman received funds from Merck; Sherman served as a consultant to Merck on one occasion in 2012.
Share this story on Facebook, Twitter, and Google:
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by University of Cincinnati Academic Health Center.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
M. H. Eckman, A. H. Talal, S. C. Gordon, E. Schiff, K. E. Sherman. Cost-effectiveness of Screening for Chronic Hepatitis C Infection in the United States. Clinical Infectious Diseases, 2013; 56 (10): 1382 DOI: 10.1093/cid/cit069
Note: If no author is given, the source is cited instead.
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.
The growing field of therapeutic ultrasound welcomes its first open access journalPublic release date: 24-Apr-2013 [ | E-mail | Share ]
Contact: Rebecca Fairbairn rebecca.fairbairn@biomedcentral.com 44-020-319-22433 BioMed Central
Open access publisher BioMed Central is proud to announce the launch of Journal of Therapeutic Ultrasound in partnership with the Focused Ultrasound Foundation and the International Society for Therapeutic Ultrasound.
Therapeutic ultrasound is a fast growing field and all parties involved believe that having a dedicated open access journal in this area can only speed up the development and eventual adoption of this important clinical tool by the wider medical community.
Focused ultrasound has the potential to be an alternative or complement for radiation therapy, the means to dissolve blood clots, and a way to deliver drugs in extremely high concentrations to a precise point in the body. It has the potential to treat a variety of serious medical disorders, including cancer, uterine fibroids, essential tremor, Parkinson's disease, epilepsy, and neuropathic pain.
"Focused ultrasound technology has enormous potential to improve the quality of lives for millions around the world," noted Neal F. Kassell, M.D., Chairman and Founder of the Focused Ultrasound Foundation. "The research reported in the Journal of Therapeutic Ultrasound will be central to advancing the field and will help accelerate the progress of focused ultrasound towards clinical adoption."
Journal of Therapeutic Ultrasound encompasses all aspects of therapeutic ultrasound, namely, the stimulus, inhibition, or modification of tissue function or structure via insonification. Led by Editors-in-Chief Arik Hananel, Focused Ultrasound Foundation, USA and Robert Muratore, Quantum Now LLC, USA, with an international editorial board consisting of the best in the field of focused ultrasound, this open access, peer-reviewed, online journal focuses mainly on translational and clinical research.
Deborah Kahn, BioMed Central's Publishing Director said, "We're very pleased to welcome the Focused Ultrasound Foundation and the International Society for Therapeutic Ultrasound as new publishing partners to BioMed Central, and we share their excitement in launching the Journal of Therapeutic Ultrasound within our growing list of society journals."
The launch edition includes two research articles. One looks at the impact of vaporized nanoemulsions on ultrasound-mediated ablation. If these results can be replicated in the clinic, microbubbles could improve the efficiency of high intensity ultrasound treatment of solid tumors. An editorial on 'The Journal of Therapeutic Ultrasound - broadening knowledge in a rapidly growing field' by Editors-in-Chief Arik Hananel and Robert Muratore, is also featured.
All Article-Processing Charges (APC) for the journal are currently covered by the Focused Ultrasound Foundation.
###
Media Contact
Rebecca Fairbairn
Public Relations Manager, BioMed Central
Tel: +44 (0) 20 3192 2433
Mob: +44 (0) 7825 257423
Email: rebecca.fairbairn@biomedcentral.com
Notes to Editors
1. Editorial
The Journal of Therapeutic Ultrasound - broadening knowledge in a rapidly growing field
Robert Muratore and Arik Hananel
Journal of Therapeutic Ultrasound 1013 1:1 doi:10.1186/2050-5736-1-1
After embargo, article available at journal website
http://www.jtultrasound.com/
Research
The impact of vaporized nanoemulsions on ultrasound-mediated ablation
Peng Zhang, Jonathan A Kopechek and Tyrone M Porter
Journal of Therapeutic Ultrasound 1013 1:2 doi:10.1186/2050-5736-1-2
After embargo, article available at journal website
http://www.jtultrasound.com/
Research
MR-guided Focused Ultrasound Technique in Functional Neurosurgery: Targeting Accuracy
David Moser, Eyal Zadicario, Gilat Schiff and Daniel Jeanmonod
Journal of Therapeutic Ultrasound 1013 1:3 doi:10.1186/2050-5736-1-3
After embargo, article available at journal website
http://www.jtultrasound.com/
Editorial
Telling it like it is
Adam Shaw and Gail R ter Haar
Journal of Therapeutic Ultrasound 1013 1:4 doi:10.1186/2050-5736-1-4
After embargo, article available at journal website
http://www.jtultrasound.com/
2. Journal of Therapeutic Ultrasound encompasses all aspects of therapeutic ultrasound, namely, the stimulus, inhibition, or modification of tissue function or structure via insonification. This open access, peer-reviewed, online journal focuses mainly on translational and clinical research. The goal is to accelerate the adoption of therapeutic ultrasound as a clinical tool.
3. BioMed Central is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector. @BioMedCentral
4. The Focused Ultrasound Foundation was created to improve the lives of millions of people worldwide by accelerating the development and adoption of focused ultrasound therapies. The Foundation works to clear the path to global adoption by coordinating and funding research and educational activities, creating partnerships and fostering collaboration among stakeholders, and building awareness of the technology among patients and professionals. The Foundation is dedicated to ensuring that focused ultrasound finds its place as a mainstream therapy for uterine fibroids, cancer, brain tumors, Parkinson's disease, epilepsy, stroke and other life-threatening conditions within years, not decades. Since its establishment in 2006, the Foundation has become the largest non-governmental source of funding for
focused ultrasound research. More information about the Charlottesville, Virginia based Foundation can be found at http://www.fusfoundation.org.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
The growing field of therapeutic ultrasound welcomes its first open access journalPublic release date: 24-Apr-2013 [ | E-mail | Share ]
Contact: Rebecca Fairbairn rebecca.fairbairn@biomedcentral.com 44-020-319-22433 BioMed Central
Open access publisher BioMed Central is proud to announce the launch of Journal of Therapeutic Ultrasound in partnership with the Focused Ultrasound Foundation and the International Society for Therapeutic Ultrasound.
Therapeutic ultrasound is a fast growing field and all parties involved believe that having a dedicated open access journal in this area can only speed up the development and eventual adoption of this important clinical tool by the wider medical community.
Focused ultrasound has the potential to be an alternative or complement for radiation therapy, the means to dissolve blood clots, and a way to deliver drugs in extremely high concentrations to a precise point in the body. It has the potential to treat a variety of serious medical disorders, including cancer, uterine fibroids, essential tremor, Parkinson's disease, epilepsy, and neuropathic pain.
"Focused ultrasound technology has enormous potential to improve the quality of lives for millions around the world," noted Neal F. Kassell, M.D., Chairman and Founder of the Focused Ultrasound Foundation. "The research reported in the Journal of Therapeutic Ultrasound will be central to advancing the field and will help accelerate the progress of focused ultrasound towards clinical adoption."
Journal of Therapeutic Ultrasound encompasses all aspects of therapeutic ultrasound, namely, the stimulus, inhibition, or modification of tissue function or structure via insonification. Led by Editors-in-Chief Arik Hananel, Focused Ultrasound Foundation, USA and Robert Muratore, Quantum Now LLC, USA, with an international editorial board consisting of the best in the field of focused ultrasound, this open access, peer-reviewed, online journal focuses mainly on translational and clinical research.
Deborah Kahn, BioMed Central's Publishing Director said, "We're very pleased to welcome the Focused Ultrasound Foundation and the International Society for Therapeutic Ultrasound as new publishing partners to BioMed Central, and we share their excitement in launching the Journal of Therapeutic Ultrasound within our growing list of society journals."
The launch edition includes two research articles. One looks at the impact of vaporized nanoemulsions on ultrasound-mediated ablation. If these results can be replicated in the clinic, microbubbles could improve the efficiency of high intensity ultrasound treatment of solid tumors. An editorial on 'The Journal of Therapeutic Ultrasound - broadening knowledge in a rapidly growing field' by Editors-in-Chief Arik Hananel and Robert Muratore, is also featured.
All Article-Processing Charges (APC) for the journal are currently covered by the Focused Ultrasound Foundation.
###
Media Contact
Rebecca Fairbairn
Public Relations Manager, BioMed Central
Tel: +44 (0) 20 3192 2433
Mob: +44 (0) 7825 257423
Email: rebecca.fairbairn@biomedcentral.com
Notes to Editors
1. Editorial
The Journal of Therapeutic Ultrasound - broadening knowledge in a rapidly growing field
Robert Muratore and Arik Hananel
Journal of Therapeutic Ultrasound 1013 1:1 doi:10.1186/2050-5736-1-1
After embargo, article available at journal website
http://www.jtultrasound.com/
Research
The impact of vaporized nanoemulsions on ultrasound-mediated ablation
Peng Zhang, Jonathan A Kopechek and Tyrone M Porter
Journal of Therapeutic Ultrasound 1013 1:2 doi:10.1186/2050-5736-1-2
After embargo, article available at journal website
http://www.jtultrasound.com/
Research
MR-guided Focused Ultrasound Technique in Functional Neurosurgery: Targeting Accuracy
David Moser, Eyal Zadicario, Gilat Schiff and Daniel Jeanmonod
Journal of Therapeutic Ultrasound 1013 1:3 doi:10.1186/2050-5736-1-3
After embargo, article available at journal website
http://www.jtultrasound.com/
Editorial
Telling it like it is
Adam Shaw and Gail R ter Haar
Journal of Therapeutic Ultrasound 1013 1:4 doi:10.1186/2050-5736-1-4
After embargo, article available at journal website
http://www.jtultrasound.com/
2. Journal of Therapeutic Ultrasound encompasses all aspects of therapeutic ultrasound, namely, the stimulus, inhibition, or modification of tissue function or structure via insonification. This open access, peer-reviewed, online journal focuses mainly on translational and clinical research. The goal is to accelerate the adoption of therapeutic ultrasound as a clinical tool.
3. BioMed Central is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector. @BioMedCentral
4. The Focused Ultrasound Foundation was created to improve the lives of millions of people worldwide by accelerating the development and adoption of focused ultrasound therapies. The Foundation works to clear the path to global adoption by coordinating and funding research and educational activities, creating partnerships and fostering collaboration among stakeholders, and building awareness of the technology among patients and professionals. The Foundation is dedicated to ensuring that focused ultrasound finds its place as a mainstream therapy for uterine fibroids, cancer, brain tumors, Parkinson's disease, epilepsy, stroke and other life-threatening conditions within years, not decades. Since its establishment in 2006, the Foundation has become the largest non-governmental source of funding for
focused ultrasound research. More information about the Charlottesville, Virginia based Foundation can be found at http://www.fusfoundation.org.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_sFnm6AEsDEaKIXVU0OE3PizUqTPlku-mPmrADO_lx0GM97UeA2DPDsdUCok4mQvQSs_Tv1JCWWAN7PtzAqI0mT-HK4dKanugnkdr5MWCo=s0-d){kind=small}
Public release date: 24-Apr-2013
Share ]